NHS subcutaneous immunotherapy 2026: who qualifies, what to expect, and how to ask your oncologist

The NHS has approved a subcutaneous (under-the-skin) formulation of pembrolizumab — one of the most widely used cancer immunotherapy drugs — reducing a typical hospital appointment from several hours to roughly five minutes. For patients juggling treatment with work, caring responsibilities, or travel, the practical difference is significant.

This guide explains what immunotherapy is, how the new injection differs from the standard intravenous drip, which cancer types it covers, and what to say to your oncologist if you want to discuss switching.

Nothing in this article constitutes medical advice. Decisions about cancer treatment must be made with your clinical team.

Immunotherapy in one sentence

Immunotherapy does not attack cancer cells directly — it removes the brakes that cancer places on your immune system, allowing your own T-cells to find and destroy the tumour.

Pembrolizumab (brand name Keytruda) blocks a protein called PD-1, which some cancers exploit to hide from immune surveillance. It is already approved by NICE for lung cancer, melanoma, head and neck cancers, bladder cancer, and several other tumour types — typically in patients whose cancer expresses the PD-L1 protein above a certain threshold.

Injection vs drip: the practical difference

The intravenous version requires a cannula, a drip set-up, and a monitored infusion over 30–60 minutes — plus waiting time either side. The total hospital visit often runs to three or four hours.

The subcutaneous formulation is a single injection into the abdomen or thigh, administered by a nurse in around five to eight minutes. Patients are still observed for a short period afterwards, but day-unit bed space is freed up considerably.

Bottom line: Same drug, same mechanism, markedly shorter visit. For patients on long-term maintenance therapy, switching to subcutaneous can reclaim dozens of hospital hours over a treatment course.

Photo by Jo McNamara on Pexels

Which patients are eligible

NICE approval does not automatically mean every pembrolizumab patient switches immediately. Eligibility depends on:

• Cancer type and PD-L1 score — your oncology team will know your biomarker profile
• Treatment line — some approvals apply to first-line, others to later lines
• Renal and hepatic function — certain absorption factors affect suitability
• Patient preference — some patients prefer IV because it comes with built-in monitoring time they find reassuring

The subcutaneous option is not a downgrade. Clinical trial data showed non-inferior efficacy and a comparable safety profile to IV. The main side-effects — fatigue, skin reactions, thyroid changes — are similar for both routes.

Questions to ask at your next appointment

If you are currently receiving pembrolizumab by infusion, these are the right starting points:

1. "Is the subcutaneous formulation now available at this centre for my cancer type?"
2. "Do my PD-L1 results and treatment history make me eligible?"
3. "Are there any reasons the injection route would not suit me specifically?"
4. "What happens if I have a reaction to the injection — is the monitoring protocol the same?"

Your oncologist or specialist nurse is the right person to ask. Not every hospital will have rolled out the subcutaneous option at the same pace — implementation depends on pharmacy and nursing training locally.

Photo by Ivan S on Pexels

Side effects: are they different from the IV version?

Clinical trial data comparing IV and subcutaneous pembrolizumab showed the safety profiles are broadly similar. The most commonly reported effects for both routes include:

• Fatigue — present in roughly 30% of patients
• Skin reactions — rash, itching, or dryness
• Thyroid dysfunction — hypothyroidism or hyperthyroidism, often manageable with medication
• Immune-related adverse events — less common but serious; colitis, pneumonitis, hepatitis

The subcutaneous route adds one new consideration: injection-site reactions. Around 5–10% of patients in trials experienced localised redness, swelling, or discomfort at the injection point. These are typically mild and resolve within 24 hours.

Your clinical team will continue to monitor you with regular blood tests regardless of which route you are on. Switching to subcutaneous does not reduce the monitoring schedule.

What if my hospital has not yet rolled out subcutaneous pembrolizumab?

NHS implementation of newly approved formulations is not instantaneous. Pharmacy procurement, nursing training, and administrative system updates all take time. If your oncologist confirms you are eligible but the option is not yet available at your centre, you can:

1. Ask your clinical nurse specialist to flag your interest formally — some centres prioritise patients with practical travel barriers
2. Contact the NHS England cancer team for your region if you feel the delay is causing undue hardship
3. Request a second opinion at a larger cancer centre if your local unit is significantly behind the rollout curve

Patience is usually appropriate here. NICE approval means the treatment must be made available — it is a question of when, not whether.

Where to find official NHS information

NHS immunotherapy overviewOfficial NHS guidance on how immunotherapy works and what to expect →

NICE technology appraisal — pembrolizumab subcutaneousFull eligibility criteria and clinical evidence reviewed by NICE →

Standout benefits for patients aged 45–65

Many patients in this age group are still working, have caring responsibilities, or live some distance from a major cancer centre. Shorter appointments mean:

• Fewer full days lost from work or caring duties
• Reduced travel burden — a 90-minute round trip for a 30-minute appointment is far less disruptive than a half-day stay
• Lower infection-risk exposure in hospital settings
• More predictable scheduling — the short visit fits around school runs, work meetings, or caring for elderly parents

The emotional dimension matters too. A long infusion day can feel like cancer is dominating life. A brief, routine injection can shift the psychological register — treatment becomes something you do quickly and move on from.

Always discuss any change to your treatment with your oncology team. This article summarises publicly available NHS and NICE information only.